Cannabis-Based Medicine for Neuropathic Pain and Spasticity—A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 1,28 MB, PDF-dokument
Keywords: cannabis-based medicine (CBM); delta-9-tetrahydrocannabinol (THC); cannabidiol (CBD); neuropathic pain (NP); spasticity
Originalsprog | Engelsk |
---|---|
Artikelnummer | 1079 |
Tidsskrift | Pharmaceuticals |
Vol/bind | 16 |
Udgave nummer | 8 |
Antal sider | 18 |
ISSN | 1424-8247 |
DOI | |
Status | Udgivet - 2023 |
Eksternt udgivet | Ja |
Bibliografisk note
Funding Information:
The Danish Ministry of Health, The Danish Multiple Sclerosis Society, Bdr. Hartmann Foundation, Karen A Tolstrup Foundation, “Direktør Ejnar Jonasson kaldet Johnsen og Hustru’s Mindelegat”, Foundation for Research in Neurology, Lykfeldts Fond, and Familien Hede Nielsens Fond.
Funding Information:
J.S.H., J.R.H., C.A., M.K., H.R., A.O., H.H.N., E.A.S., N.A. and F.B.-S. declare no conflicts of interest. S.G. has received support for congress participation from Merck. H.K. has served on scientific advisory boards for Lundbeck A/S and Novartis and has received travel grants from IPSEN and Merck. K.B.S. has served as a consultant for Takeda Pharma A/S and received travel grants from TEVA, Biogen, Merck, and Novartis. N.B.F. has received consultancy fees from Almirall, NeuroPN, Vertex, Nanobiotix, and Novartis Pharma, and has undertaken consultancy work for Aarhus University with remunerated work for Biogen, Merz, and Confo Therapeutics. She has received grants from IMI2PainCare, an EU IMI 2 (Innovative Medicines Initiative) public-private consortium, and the companies involved are Grunenthal, Bayer, Eli Lilly, Esteve, and Teva. P.V.R. has received speaker honoraria from Biogen, Roche, Merck, Alexion, and Novartis; support for congress participation from Merck, Roche, and Sanofi; and fees for serving on advisory boards from Bristol–Myers–Squibb, Merck, Roche, Novartis, Biogen, Sanofi, and Alexion. H.H.C. reports non-financial support from Merck, non-financial support from Teva, non-financial support from Biogen, and non-financial support from Roche, outside the submitted work. F.S. has served on scientific advisory boards, as a consultant for, supported congress participation, or received speaker honoraria from Alexion, Biogen, Bristol–Myers–Squibb, H. Lundbeck A/S, Merck, Novartis, Roche, and Sanofi Genzyme. His laboratory has received research support from Biogen, Merck, Novartis, Roche, and Sanofi Genzyme. RMH has received support for congress participation from Merck, Ipsen, and speaker honoraria from AbbVie. ABO has served on scientific advisory boards for Biogen Idec, Novartis, and Sanofi Genzyme; has received research support from Novartis; has received speaker honoraria from Biogen, Novartis, and TEVA; and has received support for congress participation from Merck, TEVA, Biogen, Roche, Novartis, and Sanofi Genzyme. T.P. has received research support for the MS clinic at Aarhus University Hospital from Merck, Alexion, Roche, Biogen, Novartis, and Sanofi.
Publisher Copyright:
© 2023 by the authors.
ID: 396844453